{
  "docId": "019de076-86c0-778c-b811-8ed1a345f3e4",
  "docSlug": "3a23784462a131093cb118313f70597a",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 30,
  "notes": "The slide highlights that DA-1726 achieves weight loss through mechanisms other than just food reduction, as evidenced by higher food intake compared to Tirzepatide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/19",
  "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4",
  "deckJsonHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4.json",
  "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Plasma Biochemistry Analysis",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b942f300-f464-43a6-84d3-c5dfa540789d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Cumulative Food intake in HF-DIO Obese Mice",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d891a8d2-2d2b-47cb-aa61-e3645ff50ffc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "BWL in HF-DIO Obese Mice",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f70cc6fc-ddb5-468e-9c80-6a7997b096eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.4,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Weight loss is attributed to reduced food intake and increased energy expenditure",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be277901-1fc6-4897-947a-65a3066d3133",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Notes: HF-DIO (High Fat-Diet Induced Obesity); BWL (Body Weight Loss). 1. Dong-A Study Report 105497. All treatments given as twice weekly injections. 2. Jung I-H et al. 83rd Meeting of the American Diabetes Association. 2023; Abstract 1668-P.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fcd22fd-bffb-4023-97a3-e1de79fe2e7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "DA-1726 shows similar weight loss while consuming more food compared to Tirzepatide (Mounjaro™)",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b28f64da-c620-4f08-b438-2f7c11bf7ed6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DA-1726: Therapeutic Potential in Obesity (1,2) - Tirzepatide Comparison",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "503eaa43-b6f2-4345-bf3c-150668cb2bb3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "4f28a651-1ec5-4bd3-899a-350b0daa7f8b",
      "evidence": "Direct comparison of drug efficacy metrics between DA-1726 and Tirzepatide",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}